Direct answer
Bisphosphonates and denosumab can rarely be associated with medication-related osteonecrosis of the jaw, or MRONJ. The risk is generally low with osteoporosis-dose therapy and much higher with oncology-dose regimens. Implant surgery may be reasonable in selected low-risk patients, but elective implant placement is usually approached very cautiously or avoided in patients receiving high-dose antiresorptive therapy for cancer.
Key takeaways
- MRONJ risk is not the same for oral osteoporosis medication, injectable osteoporosis therapy, and high-dose cancer therapy.
- The benefit of preventing hip and vertebral fractures often outweighs the low jaw risk of osteoporosis-dose treatment.
- Denosumab should not be casually delayed or stopped because rebound bone loss and vertebral fractures can occur.
- No blood test reliably predicts whether an individual patient will develop MRONJ after implant surgery.
- Informed consent should address both early surgical healing and the possibility that an implant site could become problematic years later.
Evidence and decision snapshot
| Question | Established role | Possible value | Important limitation |
|---|---|---|---|
| Oral bisphosphonate for osteoporosis | MRONJ is rare. | Implant treatment may be considered after individualized review. | Risk rises with duration, comorbidities, infection, and invasive surgery. |
| Injected osteoporosis-dose denosumab | Fracture prevention is important; jaw risk remains low but real. | Treatment timing may sometimes be coordinated. | Unplanned interruption can cause rebound vertebral fractures. |
| High-dose antiresorptive for cancer | MRONJ risk is substantially higher. | Necessary dental care can still be coordinated. | Elective implant placement is generally unfavorable and requires specialist input. |
| Existing implant before medication | The implant does not automatically need removal. | Maintenance and infection control can reduce complications. | Peri-implantitis or future surgery may increase risk. |
What MRONJ means
MRONJ is a clinical condition involving exposed bone, or bone that can be probed through a fistula, persisting in the maxillofacial region in a patient with relevant medication exposure and without a history of jaw radiation or metastatic disease to the jaw. Staging and diagnostic criteria are defined in professional guidance. Pain is not required, and early disease may present with nonspecific symptoms, swelling, altered sensation, drainage, or delayed healing.
The condition is uncommon in osteoporosis patients but can be difficult to treat when it occurs. That makes prevention, early recognition, and proportionate risk discussion important. The risk should not be exaggerated to the point that patients abandon medically necessary fracture prevention, nor minimized when the proposed dental procedure is elective and extensive.
Why dose and indication matter so much
Antiresorptive agents used for osteoporosis are typically delivered at lower cumulative intensity than regimens used to prevent skeletal complications from multiple myeloma or solid-tumor bone metastases. Oncology patients may also have chemotherapy, corticosteroid exposure, anemia, immunosuppression, malnutrition, and active cancer, all of which can change healing and infection risk.
Oral bisphosphonates remain in bone for a prolonged period. Denosumab does not bind bone in the same way, but its effect on bone turnover is potent and time-dependent. These pharmacologic differences are why a single rule such as “stop the drug for three months” is not scientifically adequate for every agent.
Implants, extractions, and other bone-invasive procedures
Tooth extraction is the most commonly recognized precipitating procedure, but MRONJ can occur spontaneously or around periodontal and peri-implant infection. Implant placement, grafting, explantation, and peri-implant surgery all involve bone and therefore deserve the same structured review. A small, uncomplicated procedure is not equivalent to a full-arch reconstruction with multiple extractions and grafts.
Existing implants placed before antiresorptive therapy generally do not require preventive removal. The priority is plaque control, restoration design that permits cleaning, regular examination, and prompt management of mucositis or peri-implantitis. Removing a stable implant also creates a bone wound and is not risk-free.
Drug holidays and timing decisions
Professional guidance acknowledges uncertainty regarding drug holidays. For bisphosphonates, residual skeletal effects persist after discontinuation, so a short interruption may not meaningfully reduce risk. For denosumab, delaying treatment can produce rebound bone turnover and multiple vertebral fractures. The medical danger of interruption may exceed the theoretical dental benefit.
When coordination is considered, it should involve the prescriber and a clear plan for the dental procedure, healing interval, and resumption or next dose. The patient should never be told simply to skip an injection without medical involvement. In some cases, delaying elective implant treatment, choosing a non-surgical alternative, or completing necessary dental surgery before antiresorptive treatment begins may be more rational.
Risk indicators beyond the medication
Longer exposure, high dose, cancer indication, concurrent corticosteroids, diabetes, smoking, poor oral hygiene, periodontitis, ill-fitting dentures, anemia, and prior MRONJ can increase concern. Local infection may be especially important because infected teeth and peri-implant sites can themselves lead to bone exposure or necessitate more invasive surgery later.
This creates a prevention paradox: avoiding all necessary dental treatment can allow infection to worsen, while elective surgery adds a wound. The goal is to eliminate active disease with the least traumatic effective approach, not to postpone every procedure indefinitely.
Consent and follow-up
Consent should explain that risk estimates are population averages and cannot predict an individual outcome. It should address delayed healing, exposed bone, infection, need for prolonged care, possible implant loss, and alternatives. Patients should be instructed to report persistent pain, swelling, drainage, exposed bone, altered sensation, or a wound that does not close.
Follow-up should continue beyond initial integration. Peri-implant inflammation years later may require debridement or surgery in a patient whose medication exposure has increased. A durable implant record, maintenance schedule, and communication with future dental providers are therefore part of risk management.
Frequently asked questions
What is the actual risk with an oral bisphosphonate?
It is generally low for osteoporosis-dose therapy, but the exact estimate varies with duration and other factors. Low risk does not mean zero risk.
Is Prolia the same as a bisphosphonate?
No. Prolia is denosumab, a monoclonal antibody that suppresses bone resorption through a different mechanism. Its timing and discontinuation risks differ from bisphosphonates.
Can a CTX blood test tell whether surgery is safe?
No validated CTX threshold reliably predicts MRONJ risk for an individual patient. It should not be used as a stand-alone clearance test.
Can I keep an implant if I start antiresorptive therapy later?
Usually yes. Focus on maintenance, early control of inflammation, and keeping a record of the implant system and restoration.
Are ceramic implants exempt from MRONJ risk?
No. MRONJ relates primarily to bone turnover, medication exposure, local infection, and surgery. A zirconia fixture does not remove those biologic factors.
Questions to discuss with your implant team
- What is the exact drug, dose, route, schedule, indication, and treatment duration?
- Is this osteoporosis-dose or oncology-dose therapy?
- Can the dental problem be treated with a less invasive alternative?
- Is there active infection that should not be left untreated?
- How will medication timing be coordinated without increasing fracture or cancer-related risk?
What this means for patients: The most important distinction is not simply “bisphosphonate or no bisphosphonate.” It is osteoporosis-dose versus cancer-dose treatment, the exact drug and schedule, the condition of the mouth, and the invasiveness of the proposed surgery. Never alter antiresorptive medication without the prescriber.
Selected references
- Ruggiero SL, Dodson TB, Aghaloo T, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaws - 2022 Update. J Oral Maxillofac Surg. 2022;80(5):920-943. doi:10.1016/j.joms.2022.02.008. View source.
- American Dental Association. Osteoporosis Medications and Medication-Related Osteonecrosis of the Jaw. ADA Oral Health Topics. Accessed July 28, 2026. View source.
- Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline. J Clin Oncol. 2019;37(25):2270-2290. View source.
- Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation. Bone. 2017;105:194-199.
- Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev. 2018;69:177-187.
- Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30(1):3-23.